Senseonics (NYSE:SENS) shares are off nearly -7% today after the continuous glucose monitor maker revealed plans for a stock and debt offerings and released its preliminary second-quarter sales numbers.
Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, said it plans to float $25 million in stock (plus a 30-day, $3.8 million underwriters option) and $80 million in senior notes.
Get the full story at our sister site, Drug Delivery Business News